Marijuana and Madness: Psychiatry and Neurobiology
David Castle, Robin Murray
Cambridge University Press, May 27, 2004 - Medical
This book provides a comprehensive overview of the psychiatry and neuroscience of Cannabis sativa (marijuana), with particular emphasis on psychotic disorders. It outlines developments in our understanding of the human cannabinoid system, and links this knowledge to clinical and epidemiological facts about the impact of cannabis on mental health. Clinically focused chapters review not only the direct psychomimetic properties of cannabis, but also the impact consumption has on the courses of evolving or established mental illness such as schizophrenia. A number of controversial issues are critically explored, including whether a discrete 'cannabis psychosis' exists, and whether cannabis can actually cause schizophrenia. Effects of cannabis on mood, notably depression, are reviewed, as are its effects on cognition. This book will be of interest to all members of the mental health team, as well as to neuroscientists and those involved in drug and alcohol research.
What people are saying - Write a review
We haven't found any reviews in the usual places.
2-arachidonoylglycerol activity Addiction adolescence adult agonists American Psychiatric Association amfetamine anandamide antipsychotic anxiety assessment association between cannabis Australia baseline behaviour brain cannabidiol cannabinoid receptor cannabis abuse cannabis dependence cannabis psychosis causal cause CB1 receptor Chapter chronic clinical cognitive cohort comorbidity controls coping criteria deficits Degenhardt diagnosis dopamine dopaminergic doses drug effects of cannabinoids effects of cannabis endocannabinoid endogenous cannabinoid endogenous cannabinoid system enhance epidemiological evidence follow-up function GABAergic haloperidol hippocampus human hypothesis impaired increased inhibition intoxication knockout levels longitudinal Marijuana Mechoulam medication mental health mice motives negative symptoms neurons Neurosci neurotransmitter non-users onset outcome PANSS Pharmacol pharmacological population positive symptoms potential Psychiatry psychosis proneness psychotic disorders psychotic experiences psychotic symptoms receptor antagonist relationship between cannabis reported rimonabant risk factor sample Schizophr schizophrenia self-report significant social Solowij specific subjects substance abuse substance use disorders synaptic syndrome tests treatment Verdoux vulnerability